Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  MAP Pharmaceuticals Inc.    MAPP

SummaryQuotesNewsCompany 
News SummaryMost relevantAll newsSector newsTweets 

Map Pharmaceuticals Plans FDA Meeting To Discuss Manufacturing Issues

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2012 | 11:18pm CET

Map Pharmaceuticals Inc. (>> MAP Pharmaceuticals Inc.) plans to meet with the Food and Drug Administration during the current quarter to discuss manufacturing issues that are preventing approval of its migraine medication Levadex.

The FDA in March sent a complete response letter to the biopharmaceutical company that required Map Pharmaceuticals to address manufacturing issues, chemistry and controls issues found in an inspection of the drug maker's third-party manufacturer.

Investors have been awaiting the agency's decision on the usability of Map's inhalable drug, which delivers a common migraine treatment in an aerosol format.

President and Chief Executive Timothy S. Nelson said the company continues to work closely with partner Allergan Inc. (AGN), as it seeks to resolve the issues as quickly as possible. Allergan has a deal with Map Pharmaceuticals to jointly promote Levadex.

The company also announced that it recently was issued a third patent related to Levadex.

Map shares closed Thursday at $13.14, down 1.2%, and were inactive in after-hours trading. The stock is off nearly 27% from a 2-year high last month before the company received the FDA's complete response letter.

 
   -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com 

Stocks mentioned in the article : MAP Pharmaceuticals Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MAP PHARMACEUTICALS INC.
2013DJStrong Botox Sales Help Lift Allergan's Profits 16%
2013DJAllergan 4th-Quarter Profit Rose 16% Amid Growing Revenue, Fewer Charges
2013 MAP PHARMACEUTICALS INC. : Faruqi & Faruqi, LLP is Seeking More Cash for the Sha..
2013 MAP PHARMACEUTICALS INC. : Morgan & Morgan Announces Investigation of MAP Pharma..
2013 MAP PHARMACEUTICALS INC. : Law Office of Brodsky & Smith, LLC Announces Investig..
2013 MAP PHARMACEUTICALS INC. : Ryan & Maniskas, LLP Announces Investigation of MAP P..
2013 MAP PHARMACEUTICALS INC. : Harwood Feffer LLP Announces Investigation of MAP Pha..
2013 MAP PHARMACEUTICALS INC. : Rigrodsky & Long, P.A. Announces Investigation Of MAP..
2013 MAP PHARMACEUTICALS INC. : The Law Firm of Levi & Korsinsky, LLP Notifies Invest..
2013 MAP PHARMACEUTICALS INC. : Law Office of Brodsky & Smith, LLC Announces Investig..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
Advertisement
Sector and Competitors
1st jan.Capitalization (M$)
MAP PHARMACEUTICALS IN..0.00%0
AMGEN, INC.5.79%115 062
GILEAD SCIENCES, INC.-0.84%93 553
CELGENE CORPORATION-2.67%87 334
REGENERON PHARMACEUTIC..-1.23%38 239
ACTELION LTD1.18%23 977
More Results